Navigation Links
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth

http://www.reportlinker.com/p0660752/Neurodegenerative-Disease-Market-to-2017---Patent-Expiries-of-High-Selling-Drugs-Such-as-Aricept-Namenda-Avonex-Rebif-and-Copaxone-will-Restrain-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth", which provides insights into the Neurodegenerative Disease Market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major neurodegenerative disease including Alzheimer's disease, Multiple sclerosis, Parkinson disease, Diabetic neuropathy and also orphan neurodegenerative diseases such as Huntington's disease and A
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders
2. Gene Therapy Slows Progression of Fatal Neurodegenerative Disease in Children
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
4. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
5. Global Neurodegenerative Drugs Industry
6. US Patent Granted for a New Family of Heat Shock Protein 90 (Hsp90) Inhibitors for the Treatment of Cancer and Neurodegenerative Indications
7. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
10. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
11. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Cryoport, Inc. (NASDAQ: ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, announced today that the Company ... warrants (the "Units") under a registered public offering.  ...
(Date:7/29/2015)... , July 29, 2015  Ortho-Clinical Diagnostics, Inc. ... assays under development. The assays address a range of ... injury and cardiac troponin I. The scientific posters will ... Chemistry Annual Meeting to be held July 26 - ... "Ortho Clinical Diagnostics is emerging stronger than ...
(Date:7/29/2015)... July 29, 2015 The Judicial Panel on ... about whether to centralize Inferior vena cava (IVC) Filter ... manufacturer, Cook Medical, have already been centralized by the ... in patients at risk for a pulmonary embolism. The ... to the lungs. Claims against Bard and Cook involve ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3IVC filter litigation continues; law firm provides free information to IVC filter patients 2
... New results from an observational substudy from TRITON–TIMI ... (AHA) Scientific Sessions annual meeting showed that patients ... bypass graft surgery (CABG) had a reduced overall ... (clopidogrel) (2.3 percent versus 8.7 percent respectively, p=0.016).(1) ...
... Nov. 16, 2010 New results from an ... the American Heart Association (AHA) Scientific Sessions annual ... prior to coronary artery bypass graft surgery (CABG) ... patients treated with Plavix® (clopidogrel) (2.3 percent versus ...
Cached Medicine Technology:Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery 6Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 6
(Date:7/29/2015)... MI (PRWEB) , ... July 29, 2015 , ... ... for Southwest Michigan, changed its name in July to Kalamazoo Strength & Conditioning. ... http://www.kalamazoosc.com , and “reflects the evolution of our training center over the ...
(Date:7/29/2015)... ... 2015 , ... For the second year in a row, the management and ... 50 fastest growing companies in Jacksonville. This annual list is compiled by the Jacksonville ... team of Vast Bridges staffers were on hand to receive the award naming the ...
(Date:7/29/2015)... New York, NY (PRWEB) , ... July 29, 2015 , ... ... Petitions were approved by USCIS over the past month! I-829 approvals have been granted ... projects in Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the ...
(Date:7/29/2015)... ... July 29, 2015 , ... A June 10, 2015 article from ... ," discussed the importance of having regular skin cancer screenings from an early age. ... to ultraviolet rays. When caught early, skin cancer is rarely fatal; however, if left ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order to be ... Little City took a proactive stance and began planning the Children’s Village consisting of ... valuable support to building the third home. , “We are very pleased to have ...
Breaking Medicine News(10 mins):Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3
... retailer,s $4 drug program the largest of its kind, ... its,commitment to improving the health and wellness of its ... this,Thursday, November 8, 2007, the company will expand its ... of more than 400. The program makes commonly ...
... to medication regimen, study finds , WEDNESDAY, Nov. 7 ... with high blood pressure stick to the drug regimens ... , Older black Americans tend to have poorer anti-hypertensive ... even though adherence helps reduce hypertension-related health problems and ...
... SAN DIEGO, Nov. 7 CryoCor, Inc. (Nasdaq:,CRYO), a ... announced today that it will release its financial results ... 13, 2007 after,the close of the U.S. financial markets. ... conference call at 5:00 p.m. ET /,2:00 p.m. PT ...
... CLEVELAND, Nov. 7 JumpStart Inc., Northeast ... commitment of,$350,000 in Aria Analytics, Inc. Aria ... that measures the physical and chemical,attributes of ... acoustically,probing the sample during evaporation. (Logo: ...
... a mouse feels, thanks to a new technique which uses ... the brain which regulates appetite. , Researchers hope the ... greater understanding of why certain people become obese when others ... new study, led by researchers from Imperial College London, is ...
... on multiple fronts, researchers say , , WEDNESDAY, Nov. 7 ... VN/14-1 proved effective in treating human prostate cancer, say ... The five-week study found that daily injections of VN/14-1 ... in up to a 50 percent reduction in tumor ...
Cached Medicine News:Health News:Giant Eagle Expands Popular Generic Prescription Program and Now Offers '400 for $4' 2Health News:Spirituality Helps Older Black Women Beat Hypertension 2Health News:CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results 2Health News:Aria Analytics Receives JumpStart Investment 2Health News:Aria Analytics Receives JumpStart Investment 3Health News:Obesity research boosted by watching hunger in the brain 2Health News:Experimental Drug Fights Prostate Cancer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: